Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Sunday, Wall Street Zen reports.
Several other brokerages also recently commented on NKTR. HC Wainwright reiterated a "buy" rating and set a $185.00 price target on shares of Nektar Therapeutics in a report on Friday, October 2nd. JPMorgan Chase & Co. assumed coverage on shares of Nektar Therapeutics in a research note on Friday, August 21st. They issued a "neutral" rating and a $65.00 price objective for the company. Leerink Partners started coverage on shares of Nektar Therapeutics in a research note on Monday, October 12th. They issued an "outperform" rating and a $130.00 price objective for the company. Canaccord Genuity Group decreased their price objective on shares of Nektar Therapeutics from $153.00 to $149.00 and set a "buy" rating for the company in a report on Monday, November 16th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Nektar Therapeutics in a research note on Friday, August 28th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $130.33.
Check Out Our Latest Analysis on NKTR
Nektar Therapeutics Price Performance
Shares of NASDAQ:NKTR opened at $30.20 on Friday. The stock has a market capitalization of $1.03 billion, a P/E ratio of -4.67 and a beta of 1.44. The business has a 50-day moving average of $44.60 and a two-hundred day moving average of $64.46. Nektar Therapeutics has a fifty-two week low of $30.13 and a fifty-two week high of $109.00.
Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The biopharmaceutical company reported ($1.63) EPS for the quarter, beating analysts' consensus estimates of ($2.07) by $0.44. Nektar Therapeutics had a negative return on equity of 29.31% and a negative net margin of 339.67%. The business had revenue of $9.39 million for the quarter, compared to analyst estimates of $10.27 million. As a group, research analysts expect that Nektar Therapeutics will post -7.39 EPS for the current fiscal year.
Institutional Trading of Nektar Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. American Century Companies Inc. acquired a new position in shares of Nektar Therapeutics during the third quarter worth approximately $905,000. Virtu Financial LLC bought a new stake in shares of Nektar Therapeutics in the third quarter valued at approximately $867,000. Aquatic Capital Management LLC acquired a new stake in shares of Nektar Therapeutics in the third quarter worth $697,000. Goldman Sachs Group Inc. grew its stake in shares of Nektar Therapeutics by 171.9% in the third quarter. Goldman Sachs Group Inc. now owns 621,249 shares of the biopharmaceutical company's stock worth $37,614,000 after acquiring an additional 392,759 shares during the last quarter. Finally, K2 Principal Fund L.P. grew its stake in shares of Nektar Therapeutics by 41.7% in the third quarter. K2 Principal Fund L.P. now owns 106,939 shares of the biopharmaceutical company's stock worth $6,474,000 after acquiring an additional 31,474 shares during the last quarter. Institutional investors and hedge funds own 75.88% of the company's stock.
About Nektar Therapeutics
(
Get Free Report)
Nektar Therapeutics is a clinical-stage biopharmaceutical company based in San Francisco, California. It discovers and develops medicines, with a current focus on treatments for autoimmune and inflammatory diseases. Its lead investigational program, rezpegaldesleukin (REZPEG), is designed to stimulate regulatory T cells, which help regulate immune responses. Nektar is studying the candidate in clinical trials for immune-mediated conditions; it is not an approved medicine. Founded in 1990 as Inhale Therapeutic Systems, the company later adopted the Nektar name as it expanded its drug-development work.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Nektar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nektar Therapeutics wasn't on the list.
While Nektar Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.